AstraZeneca Takes Five: DTC Study Finds Five Risks Per Ad Is Optimal For Recall

An AstraZeneca study on consumer communication through direct-to-consumer television advertisements identifies five risks as the optimal number to include in order to ensure consumer recall of safety information